Home The Word Brain	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web	Free Abstracts

Lung Cancer

Free Subscription 05.03.2018 1 Am J Respir Crit Care Med 1 Ann Surg Oncol 6 BMC Cancer 1 Cancer Chemother Pharmacol 1 Cancer Lett 1 Clin Lung Cancer 1 Clin Nucl Med 1 Eur J Cancer 1 Eur J Cardiothorac Surg 2 Eur Respir J 1 Int J Cancer 4 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 4 J Thorac Oncol 1 Mol Cancer Ther 1 N Engl J Med 4 Oncol Rep 1 Oncologist 1 PLoS Genet 2 PLoS One 3 Thorax

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Respir Crit Care Med

1. LU M, Zhu X, Shen N
   Endotracheal and Endobronchial Metastases of Small Cell Lung Cancer.
   Am J Respir Crit Care Med. 2018 Feb 28. doi: 10.1164/rccm.201708-1773.
   PubMed     Text format    
   
   

   
   Ann Surg Oncol

2. MORENO AC, Haque W, Verma V, Fang P, et al
   Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.
   Ann Surg Oncol. 2018 Feb 26. pii: 10.1245/s10434-018-6399.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

3. MARRER E, Jolly D, Arveux P, Lejeune C, et al
   Incidence of solitary pulmonary nodules in Northeastern France: a population-based study in five regions.
   BMC Cancer. 2017;17:47.
   PubMed     Text format     Abstract available
   
   
4. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
   Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
   BMC Cancer. 2017;17:48.
   PubMed     Text format     Abstract available
   
   
5. AK G, Tada Y, Shimada H, Metintas S, et al
   Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
   BMC Cancer. 2017;17:212.
   PubMed     Text format     Abstract available
   
   
6. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
   Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
   BMC Cancer. 2017;17:327.
   PubMed     Text format     Abstract available
   
   
7. KULASINGHE A, Perry C, Kenny L, Warkiani ME, et al
   PD-L1 expressing circulating tumour cells in head and neck cancers.
   BMC Cancer. 2017;17:333.
   PubMed     Text format     Abstract available
   
   
8. SANIKINI H, Yuan JM, Butler LM, Koh WP, et al
   Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies.
   BMC Cancer. 2018;18:220.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Chemother Pharmacol

9. CUI J, Wang MC, Zhang YM, Ren MZ, et al
   Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
   Cancer Chemother Pharmacol. 2018 Feb 26. pii: 10.1007/s00280-018-3539.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Lett

10. GOU W, Zhou X, Liu Z, Wang L, et al
    CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Cancer Lett. 2018 Feb 22. pii: S0304-3835(18)30171.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

11. WU TH, Hsiue EH, Lee JH, Lin CC, et al
    Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
    Clin Lung Cancer. 2018 Feb 1. pii: S1525-7304(18)30017.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

12. KARA PO, Koc ZP, Citak EC, Nayci A, et al
    Rare Endobronchial Inflammatory Myofibroblastic Tumor in Pediatric Patient Detected on PET/CT Imaging.
    Clin Nucl Med. 2017 Jun 20. doi: 10.1097/RLU.0000000000001737.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

13. LEVY A, Faivre-Finn C, Hasan B, De Maio E, et al
    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
    Eur J Cancer. 2018;93:37-46.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

14. CHO S, Yum S, Kim K, Jheon S, et al
    Prognostic factors for post-recurrence survival in patients with completely resected Stage III (N2) non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2018 Feb 27. pii: 4912385. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Eur Respir J

15. CALVAYRAC O, Pradines A, Pons E, Mazieres J, et al
    Molecular biomarkers for lung adenocarcinoma.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    
16. DE PERROT M, Dong Z, Bradbury P, Patsios D, et al
    Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

17. WEI Y, Zhou F, Zhou H, Huang J, et al
    Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via HDAC7 mediated cytoskeleton regulation and angiogenic genes transcription.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31349.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

18. CHEN L, Douglass J, Kleinberg L, Ye X, et al
    Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Int J Radiat Oncol Biol Phys. 2018;100:916-925.
    PubMed     Text format     Abstract available
    
    
19. URBANIC JJ, Wang X, Bogart JA, Stinchcombe TE, et al
    Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
    Int J Radiat Oncol Biol Phys. 2018 Jan 31. pii: S0360-3016(18)30109.
    PubMed     Text format     Abstract available
    
    
20. ROACH MC, Robinson CG, Bradley JD
    Natural Disasters and the Importance of Minimizing Subsequent Radiation Therapy Interruptions for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018;100:836-837.
    PubMed     Text format    
    
    
21. FRENZEL T, Siekmann J, Grohmann C, Valentiner U, et al
    Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models.
    Int J Radiat Oncol Biol Phys. 2018;100:1044-1056.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

22. SIKARIA D, Tu YN, Fisler DA, Mauro JA, et al
    Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma.
    J Cancer Res Clin Oncol. 2018;144:459-468.
    PubMed     Text format     Abstract available
    
    
23. XU X, Yu S, Sun W, Qin X, et al
    MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.
    J Cancer Res Clin Oncol. 2018;144:431-438.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

24. GIROUX DJ, Van Schil P, Asamura H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.
    J Thorac Oncol. 2018 Feb 21. pii: S1556-0864(18)30131.
    PubMed     Text format     Abstract available
    
    
25. YASUDA Y, Ozasa H, Kim YH
    PD-L1 Expression in Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e40-e41.
    PubMed     Text format    
    
    
26. CHO JH, Sun JM, Lee SH, Ahn JS, et al
    Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e34-e36.
    PubMed     Text format    
    
    
27. RANDHAWA S, Moore RF, DiSesa V, Kaiser L, et al
    Role of Thoracic Surgeons in Lung Cancer Screening: Opportune Time for Involvement.
    J Thorac Oncol. 2018;13:298-300.
    PubMed     Text format    
    
    

    
    Mol Cancer Ther

28. HIRANO T, Yasuda H, Hamamoto J, Nukaga S, et al
    Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
    Mol Cancer Ther. 2018 Feb 21. pii: 1535-7163.MCT-17-1033.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

29. 
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868-870.
    PubMed     Text format    
    
    

    
    Oncol Rep

30. TIAN H, Yin L, Ding K, Xia YY, et al
    Raf1 is a prognostic factor for progression in patients with nonsmall cell lung cancer after radiotherapy.
    Oncol Rep. 2018 Feb 22. doi: 10.3892/or.2018.6277.
    PubMed     Text format     Abstract available
    
    
31. LIU J, Xing Y, Rong L
    miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
    Oncol Rep. 2018 Feb 13. doi: 10.3892/or.2018.6268.
    PubMed     Text format     Abstract available
    
    
32. BAEK JH, Yim JH, Song JY, Um HD, et al
    Knockdown of end-binding protein 1 induces apoptosis in radioresistant A549 lung cancer cells via p38 kinase-dependent COX-2 upregulation.
    Oncol Rep. 2018 Feb 22. doi: 10.3892/or.2018.6278.
    PubMed     Text format     Abstract available
    
    
33. WANG Q, Chen Y, Feng H, Zhang B, et al
    Prognostic and predictive value of HURP in nonsmall cell lung cancer.
    Oncol Rep. 2018 Feb 26. doi: 10.3892/or.2018.6280.
    PubMed     Text format     Abstract available
    
    

    
    Oncologist

34. MARRONE KA, Zhou X, Forde PM, Purtell M, et al
    A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 27. pii: theoncologist.2017-0465.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Genet

35. MILEWSKI D, Balli D, Ustiyan V, Le T, et al
    FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas.
    PLoS Genet. 2017;13:e1007097.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

36. PAK K, Kim K, Kim MH, Eom JS, et al
    A decision tree model for predicting mediastinal lymph node metastasis in non-small cell lung cancer with F-18 FDG PET/CT.
    PLoS One. 2018;13:e0193403.
    PubMed     Text format     Abstract available
    
    
37. TAMIYA M, Tamiya A, Inoue T, Kimura M, et al
    Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
    PLoS One. 2018;13:e0192227.
    PubMed     Text format     Abstract available
    
    

    
    Thorax

38. MA C, Frosch ZA, Overmoyer B, Cooper AZ, et al
    Vocal fold paralysis on positron emission tomography-CT.
    Thorax. 2018;73:97-98.
    PubMed     Text format    
    
    
39. DANTAS GC, Shoji H, Hoelz C, Funari MBG, et al
    Herpes simplex lesion mimicking left upper lobe bronchial tumour.
    Thorax. 2018;73:94-95.
    PubMed     Text format    
    
    
40. MENGOLI MC, Rossi G, Tiseo M, Barbieri F, et al
    'Turban-like' skull metastasis from pulmonary adenocarcinoma.
    Thorax. 2017;72:767-768.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: